Theravance Biopharma, Inc. (TBPH)

From the record

Theravance Biopharma, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2026-09-23) (its current reports).

From the record

Theravance Biopharma, Inc.'s 10 filed years say what it did: revenue went from $49 million in fiscal 2016 to $107 million in fiscal 2025, up 9.2% a year; it rose in 5 of 9 years; the deepest fall was 68% from fiscal 2016 to fiscal 2017; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Theravance Biopharma, Inc.'s diluted share count shrank about 11.2% a year, and dividends and buybacks returned about 99% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 20 sales (14 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Theravance Biopharma, Inc. earned about 36 cents of profit for every dollar of shareholders' money. Leverage: it owed about 39 cents per dollar of assets, and net share issuance: its share count grew 5.4% over the year (the filed statements).

From the record

Theravance Biopharma, Inc.'s standing among 315 graded names in its industry family: revenue of $107 million in fiscal 2025 ranks in the top 34% by size; a net margin of 98.5% ranks in the top 3%; revenue growth of 27.9% a year over the last 3 filed years ranks in the top 32% (its annual reports).

From the record

Theravance Biopharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Winningham, Rick E (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2014-05-14, 12.5 years (top 10% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 35%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Theravance Biopharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $168 million against no long-term debt tagged leaves 34.6% of its assets as net cash, top 43% of its family; cash from operations less capital spending is 221.9% of revenue (top 1%); research spending of 34.8% of revenue (bottom 36%) (its annual report).

From the record

Theravance Biopharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 27.9% a year over the last three filed years against 9.2% over all 10, speeding up (top 14% of its family); the newest year grew 67% (top 19%); research spending grew -16.1% a year (bottom 22%); capital spending grew -58.1% a year (bottom 15%) (its annual reports). Theravance Biopharma, Inc. reported 3 product lines in fiscal 2025: Collaborative Arrangement Revenue at $75 million (70%), Milestone at $25 million (23%), License at $8 million (7%); 1 of 1 grew against the year before (its annual report).

From the record

Theravance Biopharma, Inc.'s newest year against its own record: revenue of $107 million in fiscal 2025 came in 49.1% above the $72 million its prior three years' pace pointed to (top 19% of its family); net income of $106 million against a prior three-year average of $254 million (bottom 23%); a net margin of 98.5% against more than its whole revenue before (bottom 14%) (its annual reports).